Skip to main content
Genmab logo

Genmab — Investor Relations & Filings

Ticker · GMAB ISIN · DK0010272202 LEI · 529900MTJPDPE4MHJ122 CO Manufacturing
Open in API
Filings indexed 2,823 across all filing types
Latest filing 2016-11-09 Share Issue/Capital Cha…
Country DK Denmark
Listing CO GMAB

About Genmab

https://www.genmab.com/

Genmab is an international biotechnology company that specializes in the creation, development, and commercialization of differentiated antibody therapeutics. The company focuses on transforming the treatment of cancer and other serious diseases. By utilizing proprietary antibody technology platforms and scientific expertise, Genmab develops a pipeline of innovative medicines. Its activities span from discovery and research through clinical development to deliver novel therapies to patients.

Recent filings

Filing Released Lang Actions
Kapitalforhøjelse i Genmab som følge af udnyttelse af medarbejderwarrants
Share Issue/Capital Change Classification · 100% confidence The document is a corporate announcement from Genmab regarding a capital increase resulting from the exercise of employee warrants. It details the number of shares issued, the subscription prices, and the resulting change in the total share capital. This falls under the category of share issuance or capital changes.
2016-11-09 English
Kapitalforhøjelse i Genmab som følge af udnyttelse af medarbejderwarrants
Share Issue/Capital Change Classification · 90% confidence The document is a corporate announcement from Genmab A/S detailing a capital increase by issuing 101,459 new shares following the exercise of employee warrants, including subscription prices, total proceeds, and updates to share capital. This is an announcement of a share issuance/capital change, fitting the definition for Share Issue/Capital Change (SHA).
2016-11-09 Danish
Genmab offentliggør resultat for de første ni måneder af 2016 og opjusterer forventningerne til 2016
Interim / Quarterly Report Classification · 89% confidence The document is titled “Delårsrapport for de første ni måneder af 2016” (Interim report for the first nine months of 2016) and provides substantive financial data (net revenue, operating costs, profit, liquidity) as well as business highlights, product progress, and updated guidance. It is longer than 5,000 characters, contains actual interim period financial metrics, and is not merely a publication notice but the interim report itself. Therefore, it matches the definition of an Interim/Quarterly Report (IR). 9M 2016
2016-11-02 Danish
Genmab offentliggør resultat for de første ni måneder af 2016 og opjusterer forventningerne til 2016
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim Report for the Nine Months Ended September 30, 2016' and contains comprehensive financial statements, including consolidated key figures, income statements, balance sheets, and cash flow statements. It provides detailed management analysis of business progress and financial performance. It is not a mere announcement (RPA) as it contains 35 pages of substantive financial data and analysis, fitting the definition of an Interim/Quarterly Report (IR). 9M 2016
2016-11-02 English
Genmab offentliggør resultat for de første ni måneder af 2016 og opjusterer forventningerne til 2016
Interim / Quarterly Report Classification · 90% confidence The document is titled “Interim Report for First Nine Months Ended September 30, 2016” and contains detailed substantive financial data for the nine-month period (revenue, operating expenses, operating income, cash position, guidance tables) along with narrative business progress and an investor conference-call notice. Although it instructs readers to download the full report, the embedded content goes well beyond a brief announcement or a simple link (‘report is attached’) and includes in-depth financial data and analysis, meeting the criteria for an interim/quarterly report rather than merely an earnings release or a publication notice. Therefore, it should be classified as an Interim/Quarterly Report (IR). 9M 2016
2016-11-02 English
De amerikanske sundhedsmyndigheder tildeler Priority Review-status til daratumumab til behandling af recidiverende myelomatose
Regulatory Filings Classification · 95% confidence The document is a corporate announcement (Selskabsmeddelelse) from Genmab A/S regarding regulatory news (FDA Priority Review status for a drug). It is not a financial report, transcript, or proxy statement. It functions as a general regulatory announcement regarding company operations and product development, which falls under the 'Regulatory Filings' (RNS) category as it does not fit into more specific categories like M&A or dividend announcements.
2016-10-07 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.